EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Natural Autoantibodies in Biologic-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients: Associations with Vascular Pathophysiology

Diána Simon, Dorottya Kacsándi, Anita Pusztai, Boglárka Soós, Edit Végh, György Kerekes, Monika Bodoki, Szilvia Szamosi, Gabriella Szűcs, Zoltán Prohászka, Péter Németh iD, Tímea Berki und 1 weitere

International Journal of Molecular Sciences · 2024

DOI: 10.3390/ijms25063429 ↗

Kurz gefasst

Fachartikel in der Zeitschrift International Journal of Molecular Sciences, 2024. Verfasst von Diána Simon und 12 weiteren Autor:innen. Beteiligte Einrichtung: Department of Immunology and Biotechnology, Clinical Center, University of Pécs Medical School, 7624 Pécs, Hungary. Hauptthemen laut MEDLINE: Spondylitis, Ankylosing, Arthritis, Rheumatoid, Atherosclerosis, Biological Products. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 22 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union, Pfizer (United Kingdom), European Social Fund in the framework.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Cardiovascular (CV) morbidity and mortality have been associated with rheumatoid arthritis (RA) and ankylosing spondylitis (AS). Natural autoantibodies (nAAb) are involved in innate immunity, as well as autoimmunity, inflammation, and atherosclerosis. There have not been any studies assessing the effects of biologics on nAAbs in RA and AS, also in relation to vascular pathophysiology. Fifty-three anti-TNF-treated RA and AS patients were included in a 12-month follow-up study. Anti-citrate synthase (CS) and anti-topoisomerase I fragment 4 (TOPO-F4) IgM and IgG levels were determined by ELISA. Ultrasonography was performed to assess brachial artery flow-mediated vasodilation (FMD), common carotid intima-media thickness (ccIMT), and arterial pulse-wave velocity (PWV). Other variables were also evaluated at baseline and 6 and 12 months after treatment initiation. Anti-TNF therapy improved FMD in RA and PWV in AS and stabilized ccIMT. TNF inhibition increased anti-CS IgM and IgG, and possibly also anti-TOPO-F4 IgG levels. Various correlation analyses revealed that nAAbs might be independently involved in autoimmunity as well as changes in inflammation and vascular pathology over time in biologic-treated patients (p < 0.05). We also found associations between anti-TOPO-F4 IgG and anti-Hsp60 IgG (p < 0.05). Baseline nAAb levels or nAAb level changes might determine changes in CRP, disease activity, FMD, PWV, and ccIMT over time (p < 0.05). The interplay between arthritis and inflammatory atherosclerosis, as well as the effects of anti-TNF biologics on these pathologies, might independently involve nAAbs.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Spondylitis, AnkylosingArthritis, RheumatoidAtherosclerosisBiological ProductsHumansCarotid Intima-Media ThicknessAutoantibodiesTumor Necrosis Factor InhibitorsFollow-Up StudiesInflammationImmunoglobulin GImmunoglobulin M

Stichwörter der Autor:innen

ankylosing spondylitisanti-TNF therapybiomarkersnatural autoantibodiesrheumatoid arthritis

Substanzen

AutoantibodiesTumor Necrosis Factor InhibitorsBiological ProductsImmunoglobulin GImmunoglobulin M

Autor:innen und Institutionen

  • Department of Immunology and Biotechnology, Clinical Center, University of Pécs Medical School, 7624 Pécs, Hungary.
  • Department of Rheumatology, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
  • Intensive Care Unit, Department of Medicine, Faculty of Medicine, University of Debrecen, 4032 Debrecen, Hungary.
  • Research Laboratory, Department of Medicine and Hematology, Semmelweis University, 1125 Budapest, Hungary.

ORCID-Profile: Péter Németh, Zoltán Szekanecz

Förderung

  • European Union
  • Pfizer (United Kingdom)
  • European Social Fund in the framework
  • Pfizer Investigator Initiated Research
  • Ministry for Innovation and Technology Hungary

Zitieren

APA

Simon, D., Kacsándi, D., Pusztai, A., Soós, B., Végh, E., Kerekes, G., Bodoki, M., Szamosi, S., Szűcs, G., Prohászka, Z., Németh, P., Berki, T., & Szekanecz, Z. (2024). Natural Autoantibodies in Biologic-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients: Associations with Vascular Pathophysiology. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms25063429

Vancouver

Simon D, Kacsándi D, Pusztai A, Soós B, Végh E, Kerekes G, et al. Natural Autoantibodies in Biologic-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients: Associations with Vascular Pathophysiology. International Journal of Molecular Sciences. 2024. doi:10.3390/ijms25063429

BibTeX
@article{Simon2024,
  author = {Simon, Diána and Kacsándi, Dorottya and Pusztai, Anita and Soós, Boglárka and Végh, Edit and Kerekes, György and Bodoki, Monika and Szamosi, Szilvia and Szűcs, Gabriella and Prohászka, Zoltán and Németh, Péter and Berki, Tímea and Szekanecz, Zoltán},
  title = {Natural Autoantibodies in Biologic-Treated Rheumatoid Arthritis and Ankylosing Spondylitis Patients: Associations with Vascular Pathophysiology},
  journal = {International Journal of Molecular Sciences},
  year = {2024},
  doi = {10.3390/ijms25063429}
}
Kostenlos starten →